Shape memory polymers containing compounds with 6-arm structure and their uses

A 6-arm structured shape memory polymer with adjustable recovery temperature addresses the challenges of vascular management in arteriovenous fistulas by stabilizing blood flow and preventing complications, enhancing the effectiveness and longevity of dialysis treatments.

JP2024544601AActive Publication Date: 2024-12-03TMD LAB CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024531047
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-23
Filing Date
2022-11-23
Publication Date
2024-12-03
Estimated Expiration
2042-11-23

AI Technical Summary

Technical Problem

Existing shape memory polymers are not adequately suited for managing arteriovenous fistulas, leading to complications such as stenosis, thrombosis, and increased medical costs due to improper vascular management during dialysis.

Method used

A 6-arm structured shape memory polymer with adjustable shape recovery temperature, synthesized through ring-opening polymerization, is used to create a vascular outer wall support that stabilizes blood flow and prevents vein remodeling during arteriovenous fistula formation.

Benefits of technology

The 6-arm polymer effectively supports blood vessel transplantation, minimizing abnormal blood flow and maintaining patency, thereby reducing complications and medical costs associated with dialysis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544601000001_ABST
    Figure 2024544601000001_ABST
Patent Text Reader

Abstract

The present invention relates to a shape-memory polymer having a 6-arm structure and its use. The shape-memory polymer according to the present invention exhibits shape-memory properties through crosslinking, and the shape recovery temperature can be adjusted by adjusting the monomer. As a biocompatible material, it can be developed into a medical material such as a support for the outer wall of blood vessels.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a shape-memory polymer containing a compound having a 6-arm structure and uses thereof, and more particularly to a shape-memory polymer containing a compound having a 6-arm structure that exhibits shape-memory properties through crosslinking and whose shape recovery temperature can be adjusted by adjusting the monomer, and uses thereof. [Background technology]

[0002] Chronic renal failure is a disease in which the kidney's ability to remove waste products is reduced and cannot be restored to normal, and the treatment varies depending on the degree of reduction in kidney function. In particular, when kidney failure progresses to a severe stage, alternative treatments include dialysis to remove waste products accumulated in the blood or kidney transplantation, and as a result, the number of patients with chronic renal failure has been increasing recently, and the number of hemodialysis patients is steadily increasing.

[0003] Hemodialysis is a process in which blood passes through the dialysis membrane at a rate of 200 to 500 mL per minute and then returns to the patient's blood vessels. There is a problem in that it is impossible to move and dialysis a large amount of blood through peripheral blood vessels. Depending on the patient's vascular condition at the time of surgery, a dialysis path may be created using an artificial blood vessel with ultrasound (arteriovenous graft, AVG), but hemodialysis is generally performed using an arteriovenous fistula (AVF) that connects an artery and a vein. An arteriovenous fistula is usually created in the wrist or proximal upper limb, but when an arteriovenous fistula is created using the patient's own veins, the venous diameter increases due to arterial pressure, causing the vein to mature, which remodels the vein and allows for continuous dialysis. If a patient with chronic renal failure does not undergo a kidney transplant, hemodialysis must be continued through an arteriovenous fistula for the rest of his or her life. Therefore, vascular management is necessary for long-term use of the arteriovenous fistula. In this case, if vascular management is not performed appropriately, arteriovenous fistula complications (stenosis, thrombosis, infection, pseudoaneurysm, bleeding, increased venous pressure, congestive heart failure, steal syndrome, ischemic monolimb neuropathy, etc.) may occur. If arteriovenous fistula complications occur frequently, reoperation becomes unavoidable or the number of hospitalizations increases, resulting in a decrease in the patient's quality of life and an increase in medical expenses. In particular, in the case of arteriovenous fistula formation using an autologous vein, a vortex occurs at the junction of the artery and vein due to the difference in physical properties between the artery and vein and strong arterial blood, which causes the formation of a thrombus, and ultimately causes stenosis and edema. Therefore, a method and device for preventing complications in order to extend the use of an arteriovenous fistula during dialysis is needed. Korean Patent Registration Nos. 10-1906472 and 10-2208921 disclose shape-memory polymers, their manufacturing methods, and their use as medical materials. However, there is no disclosure of a method for using the polymers as medical materials that are particularly suitable for arteriovenous fistula formation surgery, in which the shape recovery temperature can be adjusted by adjusting the monomer.

[0004] Therefore, the inventors have focused on the problems of the conventional technology and have made efforts to improve the conventional shape-memory polymer into a material that is particularly suitable for vascular management. As a result, when a compound is synthesized with a 6-arm structure as in the present invention, it is possible to adjust the shape recovery temperature by adjusting the monomer as well as the shape memory property by crosslinking. When such a shape-memory polymer is used as a medical material, it is possible to manufacture a vascular outer wall support that can prevent blood vessel clogging from a physical and biological perspective by wrapping the blood vessel from the outside, and thus completed the present invention. Summary of the Invention [Problem to be solved by the invention]

[0005] The object of the present invention is to provide a novel compound having a 6-arm structure, a method for producing the same and its use. The purpose of this invention is to provide [Means for solving the problem]

[0006] In order to achieve the above object, the present invention provides a compound represented by the following chemical formula (1): [ka] In the above chemical formula (1), x and y are each independently an integer from 1 to 20; m and n represent the mole percentage of repeat units; m+n is 100, and m may be 70-99. In the present invention, the compound is characterized in that it has shape-memory properties due to crosslinking. In the present invention, the compound is characterized in that the average shape recovery ability at a temperature of 35 to 58°C is 90% or more. The present invention also provides a method for preparing the compound, comprising the step of reacting dipentaerythritol, caprolactone, and glycidyl methacrylate. In the present invention, the reaction is characterized in that it is a ring-opening polymerization reaction. In the present invention, the reaction is carried out by 1,5,7-triazabicyclo(4.4.0)deca-5 -ene (1,5,7-Triazabicyclo(4.4.0)dec-5-ene), tin(II)(2-ethylhexanoate), trimethylolpropane tris(3-mercaptopropionate) A catalyst selected from the group consisting of thylolpropane tris(3-mercaptopropionate) and zinc succinate. The reaction is carried out in the presence of In the present invention, the production method is characterized in that dipentaerythritol, caprolactone, and glycidyl methacrylate are reacted at 80 to 140°C. The present invention also provides a shape-memory polymer in which the compound is crosslinked. The present invention also provides a method for preparing a shape memory polymer, which further comprises the step of inducing a crosslinking reaction of the compound prepared by the above preparation method. In the present invention, the crosslinking reaction is characterized by being a photocrosslinking reaction or a thermal crosslinking reaction. The present invention also provides a medical material containing the compound. In the present invention, the medical material is characterized in that it is a vascular graft support or a vascular graft stent. In the present invention, the vascular graft support is characterized in that it is a vascular outer wall support that is arranged to surround the transplanted autologous vein and artery in a side-to-end model during arteriovenous fistula formation surgery. In the present invention, the vascular outer wall support is a U-shaped anastomosis instrument. In the present invention, the vascular outer wall support includes an artery supporting portion and a graft vein supporting portion, and the angle of the tangent to the arteriovenous anastomosis site is 30° to 90°. Effect of the Invention

[0007] The 6-arm compound according to the present invention can be manufactured as a temperature-based shape-memory polymer that exhibits shape-memory properties through crosslinking, and the shape recovery temperature can be adjusted by adjusting the monomer, and it can be developed as a biocompatible medical material. In particular, by crosslinking the compound of the present invention, it is possible to manufacture a vascular outer wall support that can help the maturation of the transplanted autologous vein during arteriovenous fistula formation, minimize the occurrence of abnormal blood flow, and facilitate the flow of blood. [Brief description of the drawings]

[0008] [Figure 1] FIG. 1 is a diagram showing a synthesis mechanism of a compound having a 6-arm structure according to some embodiments of the present invention. [Diagram 2] FIG. 2 shows the 1H-NMR results for the structural analysis of a compound having a 6-arm structure according to some embodiments of the present invention. [Diagram 3] FIG. 3 is a GPC graph for molecular weight analysis of a compound having a 6-arm structure according to some embodiments of the present invention. [Figure 4] FIG. 4 is a DSC measurement graph showing the melting temperature (a) and crystallization temperature (b) of a compound having a 6-arm structure according to some embodiments of the present invention before crosslinking into a shape memory polymer. [Diagram 5] FIG. 5 is a DSC measurement graph showing the melting temperature (a) and crystallization temperature (b) of a compound having a 6-arm structure according to some embodiments of the present invention after crosslinking to a shape memory polymer. [Figure 6] FIG. 6 is a graph showing the mechanical properties of the shape memory polymer after crosslinking according to some embodiments of the present invention analyzed through UTM measurement. [Figure 7] FIG. 7 shows the results of analyzing the shape memory properties of the shape memory polymers after crosslinking according to some embodiments of the present invention through DMA measurement. [Figure 8] FIG. 8 is a photograph showing the shape memory properties of the shape memory polymers after crosslinking according to some embodiments of the present invention. [Figure 9] FIG. 9 is a schematic diagram of a shape-memory vascular outer wall support mechanism and the arrangement of arteries and veins. [Figure 10] FIG. 10 shows the results of an analysis of blood flow changes depending on the angle of the venous anastomosis. FIG. 10a shows the results of an analysis of the toe, heel, and floor areas of an arteriovenous fistula model, and FIG. 10b shows the results of an analysis of blood flow in a U-shape model. [Figure 11] FIG. 11 is a schematic diagram of a vascular outer wall support according to some embodiments of the present invention, where FIG. 11a shows the vascular outer wall support from a side view, and FIG. 11b shows the vascular outer wall support from an underside view. [Figure 12] FIG. 12 illustrates an outer vascular wall support fabricated from a shape memory polymer according to some embodiments of the present invention. [Figure 13] FIG. 13 shows the results of comparing the circumferential tensile strength of a vascular outer wall support made of a shape memory polymer according to some embodiments of the present invention with the circumferential tensile strength of a vascular outer wall support made of a shape memory polymer crosslinked with a compound having a 4-arm structure. [Figure 14] FIG. 14 shows (a) a measuring device for measuring burst strength, and (b) a result of comparing the burst strength of a vascular outer wall support made of a shape memory polymer according to some embodiments of the present invention with the burst strength of a vascular outer wall support made of a shape memory polymer crosslinked with a compound having a 4-arm structure. [Figure 15] FIG. 15 is a computer modeling result showing the structural change of a vein when the vessel wall is wrapped with an outer vessel wall support made of a shape memory polymer according to some embodiments of the present invention. [Figure 16] FIG. 16 shows an animal model of an arteriovenous fistula created through an end-to-side anastomosis of the femoral artery and femoral vein in a dog. [Figure 17] FIG. 17 shows the results of Doppler ultrasound examination of patency and blood flow pattern in the presence or absence of a vascular outer wall support made of a shape memory polymer according to some embodiments of the present invention at 3 and 6 months after vascular anastomosis. [Figure 18] FIG. 18 shows the results of angiography confirming anastomosis form and patency six months after vascular anastomosis with and without a vascular outer wall support made of a shape-memory polymer according to some embodiments of the present invention. [Figure 19] 19 shows histopathological analysis results of veins at anastomosis sites with and without a vascular outer wall support made of a shape memory polymer according to some embodiments of the present invention 6 months after vascular anastomosis. Black - elastic fiber and nucleus, yellow - collagen, light blue - mucin, red - muscle DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by a skilled artisan in the art to which this invention belongs. In general, the nomenclature used herein and the experimental methods described below are those well known and commonly used in the art. In the present invention, the term "shape memory polymer (SMP)" refers to a polymer that has the property that when an object is made to have a certain shape under specific conditions, even if the shape is changed by an external impact, the object returns to its original shape when the object is returned to the same conditions (temperature, light, pH, humidity, etc.) as when it was first made. In the present invention, the terms "comprise" or "have" and the like are intended to specify the presence of features, numbers, steps, operations, components, parts, or combinations thereof described in the specification, but are to be understood as not precluding the presence or additional possibility of one or more other features, numbers, steps, operations, components, parts, or combinations thereof.

[0010] In the present invention, epsilon-caprolactone (ε-CL) and glycidyl methacrylate (GMA) are reacted together with dipentaerythritol. It was confirmed that by cross-linking, a new polycaprolactone-based compound can be synthesized, and by forming a network between the polymer chains of the compound through cross-linking, excellent shape memory properties are imparted, and by adjusting the monomer, it is also possible to adjust the shape recovery temperature. Thus, in one aspect, the present invention relates to a compound represented by the following formula (1): [ka] In the above chemical formula (1), x and y are each independently an integer from 1 to 20; m and n represent the mole percentage of repeat units; m+n is 100, and m is an integer from 70 to 99. The shape recovery temperature of the compound of the present invention can be adjusted by adjusting the amounts of ε-caprolactone monomer and glycidyl methacrylate monomer that constitute the compound. More specifically, in the formula (1), x and y are each independently an integer of 1 to 20, which can be adjusted depending on the carbon numbers of the lactone monomer and the initiator in the step of synthesizing the compound of the formula (1). For example, when epsilon-caprolactone (ε-CL) is used, x may be 3, and when dipentaerythritol is used, y may be 1. The value of x can be adjusted by using monomers such as -acetolactone, β-propiolactone, γ-butyrolactone, δ-valerolactone, etc., and the value of y can be adjusted by using an initiator such as 6-arm PEG instead of dipentaerythritol. In the present invention, x and y can be easily adjusted by a person skilled in the art. In the chemical formula (1), m and n represent the mole percentage of the repeating unit, m+n is 100, and x may be 70-99, or 88-96, or 92-96, or 94-96. Here, mol% means the ratio of repeating units of m and n, specifically, the molar fraction. For example, in PCL-co-PGMA, it means the molar fraction of repeating units of PCL and PGMA. In the present invention, the compound is characterized in that it has shape-memory properties due to crosslinking. In the present invention, the compound has an average shape recovery ability of 90% or more, for example, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%, at a temperature of 35 to 58 ° C., or any range of 35 to 58 ° C., or any temperature of 35 to 58 ° C., for example, about 35 ° C., about 36 ° C., about 37 ° C., about 38 ° C., about 39 ° C., about 40 ° C., about 41 ° C., about 42 ° C., about 43 ° C., about 44 ° C., about 45 ° C., about 46 ° C., about 47 ° C., about 48 ° C., about 49 ° C., about 50 ° C., about 51 ° C., about 52 ° C., about 53 ° C., about 54 ° C., about 55 ° C., about 56 ° C., about 57 ° C., or about 58 ° C., but is not limited thereto.

[0011] The compounds of the present invention can be prepared by reacting α-acetolactone, β-propiolactone, γ-butyrolactone, δ-valerolactone or ε-caprolactone monomers with an acrylic monomer containing a glycidyl group and an initiator. For example, the compound of the present invention can be prepared by ring-opening polymerization of dipentaerythritol, caprolactone, and glycidyl methacrylate. In this case, the reactivity can be improved by adding a catalyst or adding a polymerization inhibitor together with or simultaneously with the initiator during the initial reaction when the polymerization conversion rate is almost zero, thereby suppressing the reaction between the temperature-sensitive glycidyl methacrylate groups. Thus, in yet another aspect, the present invention relates to a method for preparing said compound, comprising the step of reacting dipentaerythritol, caprolactone and glycidyl methacrylate.

[0012] In the present invention, the reaction is characterized in that it is a ring-opening polymerization reaction. In the present invention, the reaction is carried out using 1,5,7-triazabicyclo(4.4.0)dec-5-ene, tin(II)(2-ethylhexanoate), trimethylolpropane tris(3-mercaptopropionate), and The reaction is carried out in the presence of a catalyst selected from the group consisting of ethylolpropane tris(3-mercaptopropionate) and zinc succinate, but is not limited thereto. In particular, it is preferable to use 1,5,7-triazabicyclo(4.4.0)dec-5-ene as a catalyst to induce simultaneous ring-opening polymerization of two monomers (CL, GMA), which can shorten the synthesis time of the compound.

[0013] In the present invention, an initiator and / or a polymerization inhibitor can be added during the initial reaction, i.e., before adding glycidyl methacrylate, to inhibit the reaction between methacrylate groups. In addition, the polymerization inhibitor serves to suppress exothermic reactions that occur locally in the latter half of the polymerization and to remove unreacted residual radicals to terminate the reaction. In this way, when the initiator and polymerization inhibitor are reacted with the monomers caprolactone and glycidyl methacrylate at about 110°C for about 6 hours, the ring structure in the monomer is opened, and a 6-arm polycaprolactone-polyglycidyl methacrylate (6arm PCL-PGMA) copolymer is synthesized. In the present invention, the initiator is dipentaerythritol, and specifically, the present invention is characterized in that a 6-arm polycaprolactone-polyglycidyl methacrylate (6-arm PCL-PGMA) copolymer is synthesized by initially adding the initiator. In the present invention, the polymerization inhibitor may be one or more selected from the group consisting of hydroquinone, hydroquinone monomethyl ether, p-benzoquinone, and phenothiazine, but is not limited thereto. Preferably, the polymerization inhibitor may be hydroquinone. In the present invention, the production method is characterized in that dipentaerythritol, caprolactone and glycidyl methacrylate are reacted at 80 to 140°C, preferably 100 to 130°C, for example, at about 110°C. In this case, if the synthesis of the compound of the present invention is carried out at a temperature below 100°C, the catalytic reaction may not proceed, and if the synthesis of the compound of the present invention is carried out at a temperature exceeding 130°C, a problem of a decrease in the catalytic reaction rate may occur. In a preferred embodiment, the polymerization mechanism of the compound of the present invention can be expressed as follows.

[0014] [ka] In the present invention, the crosslinking reaction is characterized by being a photocrosslinking or thermal crosslinking reaction, but is not limited thereto. The compound of the present invention is a polymer of an ε-caprolactone monomer and an acrylic monomer containing a glycidyl group. For example, the compound may have a structure of a copolymer obtained by polymerizing an ε-caprolactone monomer (CL) and a glycidyl methacrylate (GMA) monomer [PCL-co-PGMA]. In the compound of the present invention, the ε-caprolactone monomer and the glycidyl methacrylate monomer are not particularly limited in the arrangement order, and may be arranged alternately, randomly or in a block. The copolymer may have a hydroxyl group or the like bonded to its terminal. A copolymer having a hydroxyl group bonded to its terminal can be produced by polymerization using an initiator having a hydroxyl group bonded to its terminal. The glycidyl group contained in the glycidyl methacrylate monomer may be a crosslinkable functional group, a photocrosslinkable functional group, or a thermally crosslinkable functional group. The copolymer may have shape memory properties due to crosslinking. Therefore, in yet another aspect, the present invention relates to a shape memory polymer crosslinked with the above-mentioned compound.

[0015] In yet another aspect, the present invention relates to a method for producing a shape memory polymer, further comprising the step of inducing a crosslinking reaction in the compound. In the present invention, the crosslinking agent for the crosslinking reaction may be one or more selected from the group consisting of potassium persulfate, ammonium persulfate, benzoyl peroxide, dilauroyl peroxide, dicumyl peroxide, hydrogen peroxide, azobisisobutyronitrile, Irgacure, Darocure, LAP (lithium phenyl-2,4,6-trim ethylbenzoylphosphinate), TPO (diphenyl(2,4,6-trimethylbenzoyl)phosphine), and TPO-L (ethyl(2,4,6-trimethylbenzoyl)phenylphosphinate). For example, the crosslinking agent that initiates the crosslinking reaction may be, but is not limited to, a peroxide crosslinking agent (such as benzoyl peroxide, dicumyl peroxide, etc.), Irgacure 2959, Irgacure 784, Irgacure 819, Darocur 1173, or Darocur 4265.

[0016] In addition, the compound of the present invention is a temperature-sensitive compound that is biocompatible and whose shape recovery temperature can be adjusted by adjusting the monomer. It was confirmed that when a shape-memory polymer is prepared by crosslinking a compound having a 6-arm structure compared to a compound having a 4-arm structure, the circumferential tensile strength and the compression burst strength are improved. In fact, when a vascular outer wall support is prepared using the compound of the present invention and an arteriovenous fistula formation procedure is performed, it was confirmed that the vascular U-shape is well maintained, the formation of vortex flow after vascular anastomosis is suppressed, and the arterial blood flow is smooth and excellent patency is achieved. Furthermore, it was confirmed through histological analysis that vascular stenosis through the formation of neovascular intima can be suppressed. Therefore, in yet another aspect, the present invention relates to a medical material containing the compound. In the present invention, the medical material may be produced using a shape-memory polymer obtained by crosslinking the compound. In the present invention, the medical material is characterized as being a vascular graft support or a vascular graft stent, but is not limited thereto. In the present invention, the vascular graft support is characterized in that it is a vascular outer wall support that is arranged to surround the transplanted autologous vein and artery in a side-to-end model during arteriovenous fistula formation surgery, but is not limited thereto. Such a vascular outer wall support has the characteristic of promoting maturation of the transplanted autologous vein, minimizing the occurrence of abnormal blood flow, and smoothing the flow of blood. In the present invention, the vascular outer wall support is characterized by being a U-shaped anastomosis instrument, but is not limited thereto. The U-shaped anastomosis device according to the present invention has the advantage of minimizing the occurrence of abnormal blood flow in blood vessels where arterial blood flows into venous blood, and maintaining blood flow. In the present invention, the vascular outer wall support may include an artery supporting portion and a graft vein supporting portion.

[0017] In the present invention, the angle of the tangent at the arteriovenous anastomosis site may be 30 to 90°, preferably 30 to 60°, or any range of 30 to 60°, for example, 30 to 45°, or any value of 30 to 60°, for example, about 31°, about 32°, about 33°, about 34°, about 35°, about 36°, about 37°, about 38°, about 39°, about 40°, about 41°, about 42°, about 43°, about 44°, about 45°, about 46°, about 47°, about 48°, about 49°, about 50°, about 51°, about 52°, about 53°, about 54°, about 55°, about 56°, about 57°, about 58°, about 59°, or about 60°. By adjusting the angle of the tangents at the anastomosis site according to the present invention, it is possible to prevent the formation of neointima and thus prevent vascular stenosis. In the present invention, the lower the curvature, the more stable the blood flow can be. Taking into consideration the anatomical structure, however, it is most preferable that the angle of the tangent at the arteriovenous anastomosis site is 30 to 45°, but is not limited to this. EXAMPLES

[0018] The present invention will be described in more detail with reference to the following examples. It will be obvious to those skilled in the art that these examples are merely for the purpose of illustrating the present invention and are not intended to limit the scope of the present invention. Example: 6-arm PCL-PGMA synthesis The following 6-arm PCL-PGMA copolymers were synthesized by varying the ratio of PCL to PGMA.

[0019] [Table 1] Dipentaerythritol (initiator, Sigma Aldrich) and hydroquinone (inhibitor, HQ, Sigma Aldrich) were placed in a three-neck flask, dried under vacuum for 10 minutes, and then purged with nitrogen at a rate of 50cc / min. Purified epsilon-caprolactone (ε-CL, monomer, AVENTION) was added and stirred at 110°C for 10 minutes. Then, glycidyl methacrylate (GMA, monomer, Sigma Aldrich) was added and stirred for 10 minutes, after which 1,5,7-triazabicyclo(4.4.0)dec-5-ene (TBD, catalyst, TCI) dissolved in acetonitrile (ACN, Sigma Aldrich) was added and reacted at 110°C for 6 hours. The final product was dissolved in chloroform (Daejung Chemicals & Metals CO., LTD.) and precipitated with ethyl ether (Daejung Chemicals & Metals CO., LTD.) at 4°C, filtered, and dried in vacuum. The synthesis mechanism is shown in Figure 1. The monomers are epsilon-caprolactone (ε-CL) and glycidyl methacrylate (GMA), the initiator is dipentaerythritol, and the inhibitor is hydroquinone (hydroquinone). When polycaprolactone (PGMA) is reacted with 1,2-dichlorophenyl ether (HQ) at 110°C for 6 hours, the ring structure in the monomer is opened, and a 6-arm polycaprolactone-polyglycidyl methacrylate (6-arm PCL-PGMA) copolymer is synthesized. Comparative example: 4-arm 94% PCL-06% PGMA synthesis The 4-arm PCL-PGMA copolymer was synthesized as follows.

[0020] [Table 2] Pentaerythritol (pentaerythritol, initiator, Sigma Aldrich) and hydroquinone (hydroquinone, HQ, inhibitor, Sigma Aldrich) were placed in a three-neck flask, and after vacuum drying for 10 minutes, the flask was purged with nitrogen at a rate of 50cc / min. Purified epsilon-caprolactone (ε-caprolactone, ε-CL, monomer, AVENTION) was further added and stirred at 110°C for 10 minutes. Glycidyl methacrylate (GMA, monomer, Sigma Aldrich) was then added and stirred for 10 minutes, after which 1,5,7-triazabicyclo(4.4.0)dec-5-ene (TBD, catalyst, TCI) dissolved in acetonitrile (acetonitrile, ACN, Sigma Aldrich) was poured in and reacted at 110°C for 6 hours. The final product was chloroform (Daejung Chemical The residue was dissolved in Daejung Chemicals & Metals CO., LTD., and then precipitated with ethyl ether (Daejung Chemicals & Metals CO., LTD.) at 4°C, filtered, and dried in vacuum.

[0021] <Experimental Example> Experimental Example 1: Crosslinking of copolymer compounds The synthesized copolymer compound was dissolved in N-methyl-2-pyrrolidone (NMP, Sigma Aldrich) at a ratio of 100 w / v% and Irgacure 2959 (photoinitiator, Sigma Aldrich) at a ratio of 1 w / v%. The solution was made into a film and then crosslinked using a UV lamp (365 nm / 200 s). Experimental Example 2: <Structural Analysis> 1The structure was analyzed using H-NMR (AVANCEIIIHD 400, Bruker Biospin, USA). The sample was prepared by mixing the copolymer compound synthesized in the above example with chloroform-D (Sigma Aldrich) at a concentration of 10 mg / mL. The results of the structural analysis are shown in Figure 2. PCL peaks appear at δ = 4.10 [m, -OCH2, (E)], 2.41 [m, -CH2, (A)], 1.74 [m, -CH2, (B and D)], and 1.45 [m, -CH2, (C)], and PGMA peaks appear at δ = 6.13 [s, =CH2, (G2)], 5.58 [s, =CH2, (G1)], and 1.97 [s, ​​-CH3, (F)], confirming that a compound with a 6-arm structure was synthesized. The mole percentages of PCL and PGMA were calculated by comparing the areas of the PCL peak and the PGMA peak. Experimental Example 3: Molecular weight analysis (GPC) The molecular weight of the compounds synthesized in the examples was analyzed using GPC (1260 Infinity II, Agilent). Samples were prepared by mixing the synthesized compounds and tetrahydrofuran (THF, JT Baker) at a concentration of 5 mg / ml and filtering with a 0.45 um syringe filter. The eluent was THF, the flow rate was 1 ml / min, and the column temperature was 40°C. A standard curve was prepared using PS (polystyrene, Agilent). The GPC graph showing the molecular weight of the synthesized compound is shown in Figure 3 and Table 3. It can be seen that the molecular weight of the 6-arm PCL-PGMA copolymer (Example) is larger than that of the conventional 4-arm PCL-PGMA copolymer (Comparative Example), and that in the case of the 6-arm PCL-PGMA copolymer, the molecular weight increases as the PCL content increases.

[0022] [Table 3] Experimental Example 4: Thermal property analysis (DSC) Thermal properties were analyzed using a DSC (DSC214, NETZSCH). Measurements were performed in the temperature range of -80℃ to 150℃ in heating-cooling-heating mode, with a heating and cooling rate of 10℃ / min. The results of DSC measurement before crosslinking are shown in FIG. 4 and Table 4. The comparative example is a conventional 4-arm structure of 94% PCL-06% PGMA, and the example 2 is a 6-arm structure. When comparing 94% PCL-06% PGMA, the melting temperature (Tm) and melting enthalpy (Δ m ) and crystallization enthalpy (Δ c ) was lower. This means that in the case of the 6-arm PCL-PGMA of the Example, the number of arms is increased compared to the Comparative Example, and therefore the number of end groups is increased and the proportion of PGMA is increased. The increased proportion of PGMA further hinders the crystallization of PCL, and therefore the Example shows different thermal properties from the Comparative Example. In the cases of Examples 1, 2, and 3, it can be seen that the melting temperature, melting enthalpy, and crystallization enthalpy increase as the proportion of PCL, a crystalline polymer, increases. This is also because the change in the proportion of PGMA affects the crystal formation of PCL.

[0023] [Table 4] After crosslinking, the results of DSC measurement are shown in FIG. 5 and Table 5. Crosslinking the polymer compound creates connections between the polymer chains, which results in shape memory performance, which affects the melting temperature (shape recovery temperature) after crosslinking. Also, crosslinking the synthesized compound with a 6-arm structure reduces the crystallinity, which results in a lower melting temperature than before crosslinking (compare Figures 4 and 5). In the case of Example 1, since the content of PGMA participating in the crosslinking reaction is high, it becomes amorphous as it is crosslinked, and the melting temperature and crystallization temperature do not appear. In the cases of Examples 2 and 3, the crystallinity can be adjusted by adjusting the ratio of PCL and PGMA, and the change in crystallinity affects the melting temperature. Using these characteristics, the shape recovery temperature can be adjusted by adjusting the ratio of PCL and PGMA in the 6-arm PCL-PGMA copolymer synthesized.

[0024] [Table 5] Experimental example 5: Mechanical property analysis (UTM) The mechanical properties of the shape memory polymer of the present invention were analyzed using a UTM (34SC-1, INSTRON). The sample was UV crosslinked and prepared in the form of a film with a size of W5mm x L5mm x T0.4mm, and measured at 37°C with an initial length of 10mm and a tensile speed of 10mm / min. The mechanical properties measured by UTM are shown in FIG. 6 and Table 6. Compared to the comparative example, the Young's modulus (E), stress at max (σ), and strain (ε) values ​​increased in the examples. In particular, in the case of Example 2, compared to the comparative example, Young's modulus (E) increased by 812%, stress at max (σ) increased by 383%, and strain (ε) increased by 189%. This result is because as the number of arms in the copolymer structure increases, the entanglement of chains increases, improving mechanical properties, and the PCL content increases, increasing crystallinity.

[0025] [Table 6] Experimental Example 6: Shape Memory Analysis (DMA) The shape memory properties were analyzed using DMA (Discovery DMA850, TA instrument). The samples were UV cross-linked and fabricated into a film shape with dimensions of W5mm x L5mm x T0.4mm. Maintain at 55℃ for 10 minutes (original permanent shape, ε p (0)), and then the sample was stretched to 78 kPa at a rate of 4 kPa / min to deform it. It was then cooled to 0°C at a rate of 2°C / min and held at 0°C for 10 minutes (maximum strain, ε1(N)), after which the force was released at a rate of 4 kPa / min to 0 Pa (temporary shape, ε u (N)), and the temperature was further increased to 55°C at a rate of 2°C / min (permanent shape, ε p (N)). This process constituted one cycle and was repeated a total of four times. Shape recovery rate (R r ) and shape fixity (R f ) was calculated using the following equations (1) and (2).

number

number

[0026] [Table 7] R r ,shape recovery;R f ,shape fixity;%, strain relaxation ratio compared to original length. Experimental Example 7: Design and fabrication of blood vessel outer wall support Due to the physical properties of the compound according to the present invention and the shape-memory characteristics due to crosslinking, the shape-memory polymer according to the present invention is a biocompatible material that can recover its shape by adjusting the temperature, and can be developed into a medical material such as a support for the outer wall of blood vessels. Thus, a vascular outer wall support for manufacturing a shape-memory polymer according to the present invention was designed. In one embodiment, the vascular outer wall support may be provided so as to be disposed around the transplanted autologous vein and artery in a side-to-end model during arteriovenous fistula formation surgery. In this case, the vascular outer wall support can promote maturation of the transplanted autologous vein, minimize the occurrence of abnormal blood flow, and facilitate smooth blood flow. Therefore, the vascular outer wall support according to the present invention was designed to include an artery support part and a graft vein support part, and in order to minimize the occurrence of abnormal blood flow in the blood vessel where arterial blood flows into venous blood when the vascular outer wall support anastomoses the blood vessel, a U-shaped anastomosis device was devised and curvatures were presented and compared according to the angle of the venous junction. During arteriovenous fistula formation, the areas where vascular stenosis often occurs are known to be the toe, heel, and floor area based on the anastomosis, and the analysis was conducted based on these. However, in the case of the floor area, the proximal area based on the tangent line where the vein meets the artery plays an important role in the blood flow of the arteriovenous fistula, so the proximal area of ​​the tangent line was defined as the floor area. area and proceeded with the analysis. Analysis of blood flow changes according to the angle of the venous anastomosis showed that the blood flow could be maintained in a U-shape, which is expected to induce blood flow closer to laminar flow in terms of hemodynamics than connecting blood vessels with conventional surgical methods, prevent the formation of neointima, and prevent vascular stenosis. The results showed that the lower the curvature, the more stable the blood flow, but when realistically reflecting the anatomical structure, it was determined that a curvature radius of 10 to 20 mm (approximately 30 to 40°) was particularly preferable (Figures 9 and 10). Based on the above results, a vascular outer wall support including a graft vein support portion and an artery support portion was designed and then fabricated (Figs. 11 and 12). The circumferential tensile strength of the vascular outer wall support thus fabricated was measured by pulling it in the circumferential direction using a UTM (34SC-1, INSTRON). The measurements were performed at 37°C, with an initial length of 3 mm and a pulling speed of 10 mm / min.

[0027] As a result, compared with the vascular outer wall support fabricated with a shape-memory polymer based on the Comparative Example (4 arm 94% PCL-06% PGMA), It was confirmed that the vascular outer wall support made of a PGMA-based shape memory polymer showed a certain tendency and that the circumferential tensile strength increased by an average of about 7% (Figure 13). The burst strength of the prepared vascular outer wall support was measured using a burst strength measuring device as shown in Figure 14a. The burst strength measuring device is composed of a pressure gauge, a syringe pump, and a sample fixing device, and was manufactured to measure the pressure that the balloon can withstand when it is expanded by injecting water into the balloon at a constant rate after inserting a balloon inside the sample. The venous portion of the vascular outer wall support was attached to the burst strength measuring device, and the burst pressure when the inner tube was expanded was confirmed. The measurement was performed at 37°C with distilled water injected at a rate of 10cc / min. As a result, it was confirmed that the vascular outer wall support made of the shape-memory polymer of Example 2 (6arm 94%PCL-06%PGMA) showed a certain tendency and the burst strength increased by an average of about 39% compared to the vascular outer wall support made of the shape-memory polymer of Comparative Example (4arm 94%PCL-06%PGMA) (Figure 14). Experimental Example 8. Structural changes in venous vascular walls due to application of vascular outer wall support through computer modeling In order to confirm the effect of the vascular outer wall support according to the present invention, structural changes when a vein is wrapped with the vascular outer wall support were confirmed through computer modeling. Veins are biological tissues with hyperelastic properties and do not follow the linear and nonlinear properties of other polymeric materials. Therefore, even if significant plastic deformation occurs, veins undergo elastic recovery and behave incompressible. In the present invention, parameters were calculated to simulate a homogeneous, isotropic, incompressible hyperelastic model for blood vessels. The strain energy function (W) is expressed as a function of the stretch ratio invariant and the main stretch ratio, and is defined as shown in Equation (3).

number

number

number

[0028] Six months after modeling the arteriovenous fistula, angiography was performed to confirm the condition and patency of the arteriovenous anastomosis. A catheter (6Fr) was placed in the iliac artery, iohexol was injected, and angiography was performed using a C-arm. As a result, it was confirmed that the arteriovenous anastomosis was well maintained in a U-shape and had good patency in the experimental group, in which the vascular outer wall support was inserted, compared to the control group (Figure 18). Finally, the animals were sacrificed under general anesthesia by intravenous injection of potassium chloride, and then arteriovenous anastomosis was performed. The area was harvested and histopathology was performed. The harvested blood vessels were fixed by treatment with 4% paraformaldehyde for 24 hours, embedded in paraffin wax, and the arteriovenous anastomosis area was cross-sectioned at a thickness of 5 um. The cross-sections were stained with pentachrome (StatLab, item #; KTRMP). As a result, it was confirmed that the experimental group in which the vascular outer wall support material according to the present invention was inserted had a superior effect of inhibiting the formation of neointima compared to the control group (FIG. 19).

[0029] As described above, certain parts of the present invention have been described in detail. It will be apparent to those skilled in the art that such specific techniques are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the true scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A compound represented by the following chemical formula (1): 【Chemistry 1】 In the above chemical formula (1), x and y are each independently an integer from 1 to 20; m and n represent the mole percentage of repeat units; m+n is 100 and m is 70 to 99.

2. The compound according to claim 1, characterized in that the compound has shape memory properties due to crosslinking.

3. The compound according to claim 1, characterized in that the compound has an average shape recovery ability of 90% or more at a temperature of 35 to 58° C. after crosslinking.

4. 2. The method of claim 1, comprising reacting dipentaerythritol, caprolactone, and glycidyl methacrylate.

5. The method according to claim 4, wherein the reaction is a ring-opening polymerization reaction.

6. The reaction is 1,5,7-Triazabicyclo(4.4.0)dec-5-ene, tin(II)(2-ethylhexanoate), trimethylolpropane tris(3-mercaptopropionate) 5. The method according to claim 4, wherein the reaction is carried out in the presence of a catalyst selected from the group consisting of tris(3-mercaptopropionate) and zinc succinate.

7. The method according to claim 4, characterized in that the reaction is carried out at 80 to 140°C.

8. A shape memory polymer crosslinked with the compound according to claim 1.

9. A method for producing a shape memory polymer, further comprising the step of inducing a crosslinking reaction in the compound according to claim 1 produced by the method according to any one of claims 4 to 7.

10. The method according to claim 9 , wherein the crosslinking reaction is a photocrosslinking reaction or a thermal crosslinking reaction.

11. A medical material comprising a compound according to any one of claims 1 to 3.

12. The medical material according to claim 11, characterized in that the medical material is a vascular graft support or a vascular graft stent.

13. The medical material according to claim 12, characterized in that the vascular graft support is a vascular outer wall support that is arranged to surround the transplanted autologous vein and artery in a side-to-end model during arteriovenous fistula formation surgery.

14. 14. The medical material according to claim 13, wherein the vascular outer wall support is a U-shaped anastomosis device.

15. The medical material according to claim 13, characterized in that the vascular outer wall support includes an artery support portion and a graft vein support portion, and the angle of the tangent to the arteriovenous anastomosis site is 30° to 90°.

Citation Information

Patent Citations

  • Temperature-based shape memory polymers

    JP2023532026A

  • Reinforcement method for concrete structures using flame retardant adhesive resin impregnated reinforcement fiber composites

    KR102118848B1

  • Photo-cross-linkable shape-memory polymer and preparation method therefor

    US20210102023A1

  • Biodegradable polymer compound

    WO2014061341A1

  • Self-expandable stent and method for manufacturing same

    WO2019013101A1